バイオ医薬品開発の独Evotecは13日、2013年の売上高見通しをこれまでの9,000万～1億ユーロから8,400万～8,600万ユーロに引き下げた。同社からライセンスを取得してJohnson & Johnson子会社のJanssenが進める医薬品開発プロジェクト（前臨床試験段階）が所期の成果を上げなかったため、開発の進捗に応じたマイルストーン収入が減少。これに伴い、前年実績（140万ユーロ）を上回るとしていた営業利益（特別要因を除く）も前年実績を下回るに下方修正した。
\
| Cookie | 期間 | 説明 |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |